Literature DB >> 698486

Enhancement of a nociceptive reaction by opioid antagonists in mice.

J J Jacob, K Ramabadran.   

Abstract

1. The opioid antagonists, naloxone, GPA 2163, levallorphan and Mr-2266 reduced the latency of the jumping reaction of mice in the hot plate test. The (+)-isomers of levallorphan and Mr-2266 which are devoid of antagonistic activity did not increase this latency. 2. In the same nociceptive reaction test, the enhancing effect of naloxone progressed in a dose-range similar to that required for the antagonism by naloxone of the depressive action of morphine. 3. The facilitatory effect of naloxone was not blocked by the previous administration of morphine or etorphine but it was prevented by pretreatment with a high dose of buprenorphine. 4. The antagonism by naloxone of morphine and of buprenorphine did not follow the same pattern. 5. The factors which are or may be involved in the efficacy of naloxone in enhancing nociceptive reactions are discussed. 6. The enhancing effect of naloxone may be due to an antagonism of endogenous ligands for the opiate receptor. If so, these ligands would be involved in reaction to but not in perception of nociceptive stimuli which need not be harmful ones.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 698486      PMCID: PMC1668273          DOI: 10.1111/j.1476-5381.1978.tb08645.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

1.  [Action of some analgesics on the behavior of mice exposed to a thermoanalgesic stimulus. II. Immediate nociceptive response. Differential actions of analgesic and psychoactive substances on the leeching and jumping reactions].

Authors:  J JACOB; M BLOZOVSKI
Journal:  Arch Int Pharmacodyn Ther       Date:  1961-10-01

2.  Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse.

Authors:  T J HALEY; W G MCCORMICK
Journal:  Br J Pharmacol Chemother       Date:  1957-03

3.  The measurement of pain; prototype for the quantitative study of subjective responses.

Authors:  H K BEECHER
Journal:  Pharmacol Rev       Date:  1957-03       Impact factor: 25.468

4.  STUDIES ON PAIN. A NEW METHOD FOR MEASURING PAIN THRESHOLD: OBSERVATIONS ON SPATIAL SUMMATION OF PAIN.

Authors:  J D Hardy; H G Wolff; H Goodell
Journal:  J Clin Invest       Date:  1940-07       Impact factor: 14.808

5.  Opioid peptides and opiates differ in receptor selectivity.

Authors:  L Terenius
Journal:  Psychoneuroendocrinology       Date:  1977       Impact factor: 4.905

6.  Naloxone blockade of acupuncture analgesia: endorphin implicated.

Authors:  B Pomeranz; D Chiu
Journal:  Life Sci       Date:  1976-12-01       Impact factor: 5.037

Review 7.  The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone.

Authors:  B A Berkowitz
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

8.  Endogenous opioid peptides: multiple agonists and receptors.

Authors:  J A Lord; A A Waterfield; J Hughes; H W Kosterlitz
Journal:  Nature       Date:  1977-06-09       Impact factor: 49.962

9.  Effect of opiate receptor blockade on pain sensitivity in the rat.

Authors:  G G Berntson; J M Walker
Journal:  Brain Res Bull       Date:  1977 Mar-Apr       Impact factor: 4.077

10.  Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.

Authors:  A Cowan; J W Lewis; I R Macfarlane
Journal:  Br J Pharmacol       Date:  1977-08       Impact factor: 8.739

View more
  16 in total

1.  Phytochemical characterization and antinociceptive effect of Lippia gracilis Schauer.

Authors:  Adriana G Guimarães; Silvana V F Gomes; Valéria R S Moraes; Paulo C L Nogueira; Antônio G Ferreira; Arie F Blank; Alan D C Santos; Monalisa D Viana; Geraldo H Silva; Lucindo J Quintans Júnior
Journal:  J Nat Med       Date:  2011-10-22       Impact factor: 2.343

2.  A critical analysis of the experimental evaluation of nociceptive reactions in animals.

Authors:  K Ramabadran; M Bansinath
Journal:  Pharm Res       Date:  1986-10       Impact factor: 4.200

3.  Potentiation of pentazocine analgesia by low-dose naloxone.

Authors:  J D Levine; N C Gordon; Y O Taiwo; T J Coderre
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

4.  "Paradoxical" analgesia induced by naloxone and naltrexone.

Authors:  J D Greeley; A D Lê; C X Poulos; H Cappell
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  Effect of naloxone on the behaviour of rats exposed to a novel environment.

Authors:  R J Rodgers; R M Deacon
Journal:  Psychopharmacology (Berl)       Date:  1979-09       Impact factor: 4.530

6.  Anti-inflammatory and analgesic effects of 6α,7β-dihydroxy-vouacapan-17β-oic acid isolated from Pterodon emarginatus Vog. fruits.

Authors:  Camila Benatti Galceran; Jayme Antonio Aboin Sertie; Clarissa Silva Lima; José Carlos Tavares Carvalho
Journal:  Inflammopharmacology       Date:  2011-03-08       Impact factor: 4.473

7.  Delayed effects of naloxone on responsiveness to environmental novelty in rats.

Authors:  R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

8.  Naloxone-induced analgesia and morphine supersensitivity effects are contingent upon prior exposure to analgesic testing.

Authors:  C X Poulos; D M Knoke; A D Le; H Cappell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

9.  Effects of intrathecally administered pentobarbital and naloxone on the activity evoked in ascending axons of the rat spinal cord by stimulation of afferent A and C fibres. Further evidence for a tonic endorphinergic inhibition in nociception.

Authors:  G Bernatzky; T Doi; I Jurna
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-07       Impact factor: 3.000

10.  Intrathecal substance P depresses spinal motor and sensory responses to stimulation of nociceptive afferents--antagonism by naloxone.

Authors:  T Doi; I Jurna
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-05       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.